Tech Company Financing Transactions
KymaThera Funding Round
KymaThera secured a $80 million Series B funding round on 10/6/2026. Investors included Alta Partners, Foresite Capital and J. Wood Capital.
Transaction Overview
Company Name
Announced On
10/6/2026
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the advancement of K-1728, its investigational, oral and pan-mutant selective PI3Ka inhibitor.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3570 Carmel Mountain Rd 200
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Undisclosed
Website
Email Address
Overview
KymaThera is a discovery-stage biotechnology company developing best-in-class medicines for serious diseases. KymaThera's leadership team brings decades of experience advancing small-molecule therapeutics from concept to clinic, with a record of success spanning multiple therapeutic areas and dozens of development candidates and approved medicines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rob Kania
Chief Financial Officer
Michael Geremia
Chief Medical Officer
Cassandra Choe-Juliak
Chief Scientific Officer
Jason Cox
Founder
Brooke Grandinetti
Founder
Shawn Ouyang
Browse more venture capital transactions:
Prev: 10/6/2026: SereNeuro Therapeutics venture capital transaction
Next: 10/6/2026: TextYess venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs